Docosahexaenoic Acid (DHA) Supplementation in a Triglyceride Form Prevents from Polyglutamine-Induced Dysfunctions in Caenorhabditis elegans
Por:
I. MORA, A. TEIXIDÓ, R. VAZQUEZ-MANRIQUE, F. PUIGGRÒS and L. AROLA
Publicada:
1 dic 2024
Resumen:
A common hallmark of neurodegenerative diseases is the accumulation of polypeptide aggregates in neurons. Despite the primary cause of these diseases being inherently genetic, their development can be delayed with proper preventive treatments. Long-chain polyunsaturated fatty acids (omega-3 LCPUFA) are promising bioactive nutrients that are beneficial for brain health. In this study, the impact of an oil rich in a structured form of docosahexaenoic acid (DHA) triglyceride (TG) was assessed in a Caenorhabditis elegans model expressing long poly-glutamine (polyQ) chains, which mimics the symptomatology of polyQ-related neurodegenerative diseases such as Huntington's disease (HD), among others. The lifespan, the motility, the number of polyQ aggregates, the oxidative stress resistance, and the cognitive performance associated with sensitive stimuli was measured in mutant nematodes with polyQ aggregates. Overall, DHA-TG at 0.5 mu M improved the lifespan, the motility, the oxidative stress resistance, and the cognitive performance of the nematodes, emphasizing the protection against serotonergic synapse dysfunction. Furthermore, the treatment reduced the polyQ aggregates in the nematodes. The data described herein shed light on the connection between DHA and the cognitive performance in neurodegenerative diseases and demonstrated the potential of DHA-TG as nutritional co-adjuvant to prevent the development of polyQ-associated dysfunctions.
Filiaciones:
I. MORA:
Brudy Technol SL, Barcelona 08006, Spain
Univ Rovira i Virgili, Tarragona 43003, Spain
A. TEIXIDÓ:
Eurecat, Ctr Tecnol Catalunya, Nutr & Hlth Unit, Reus 43204, Spain
:
Inst Invest Sanitaria La Fe, Lab Mol Cellular & Genom Biomed, Valencia 46026, Spain
Inst Invest Sanitaria La Fe, Ctr Invest Principe Felipe, Joint Unit Rare Dis, Valencia 46012, Spain
Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid 28029, Spain
F. PUIGGRÒS:
Eurecat, Ctr Tecnol Catalunya, Biotechnol Area, Tarragona 43204, Spain
L. AROLA:
Univ Rovira i Virgili, Dept Bioquim & Biotecnol, Nutrigen Res Grp, Tarragona 43007, Spain
gold
|